JP2004535397A - 心細胞におけるカルシウムチャンネルの活性の調節法及びそのための試薬 - Google Patents

心細胞におけるカルシウムチャンネルの活性の調節法及びそのための試薬 Download PDF

Info

Publication number
JP2004535397A
JP2004535397A JP2002589036A JP2002589036A JP2004535397A JP 2004535397 A JP2004535397 A JP 2004535397A JP 2002589036 A JP2002589036 A JP 2002589036A JP 2002589036 A JP2002589036 A JP 2002589036A JP 2004535397 A JP2004535397 A JP 2004535397A
Authority
JP
Japan
Prior art keywords
peptide
channel
cardiac
activity
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002589036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004535397A5 (enExample
Inventor
ダルハンティ，アンジェラ・フェイ
カサロット，マーコ・ギオヴァニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian National University filed Critical Australian National University
Publication of JP2004535397A publication Critical patent/JP2004535397A/ja
Publication of JP2004535397A5 publication Critical patent/JP2004535397A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
JP2002589036A 2001-05-17 2002-05-17 心細胞におけるカルシウムチャンネルの活性の調節法及びそのための試薬 Withdrawn JP2004535397A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5066A AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
PCT/AU2002/000608 WO2002092119A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Publications (2)

Publication Number Publication Date
JP2004535397A true JP2004535397A (ja) 2004-11-25
JP2004535397A5 JP2004535397A5 (enExample) 2006-01-05

Family

ID=3829046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589036A Withdrawn JP2004535397A (ja) 2001-05-17 2002-05-17 心細胞におけるカルシウムチャンネルの活性の調節法及びそのための試薬

Country Status (11)

Country Link
US (1) US20050049198A1 (enExample)
EP (1) EP1392344A4 (enExample)
JP (1) JP2004535397A (enExample)
KR (1) KR20040002970A (enExample)
CN (1) CN1516596A (enExample)
AU (1) AUPR506601A0 (enExample)
BR (1) BR0210902A (enExample)
CA (1) CA2446839A1 (enExample)
NZ (1) NZ529940A (enExample)
WO (1) WO2002092119A1 (enExample)
ZA (1) ZA200309727B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011174707A (ja) * 2010-02-23 2011-09-08 Kanazawa Univ 心筋障害の検査方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109306011B (zh) * 2018-09-27 2021-08-03 中国人民解放军第二军医大学 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途
CN119876003B (zh) * 2025-01-21 2026-04-24 深圳大学 一种肌质网钙泵囊泡的分离纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
DE4110785A1 (de) * 1991-04-04 1992-10-08 Bayer Ag Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung
AU1890092A (en) * 1991-04-18 1992-11-17 Indiana University Foundation Novel ester derivatives of ryanodine and dehydroryanodine
EP1218407A4 (en) * 1999-09-22 2003-01-08 Cognetix Inc USES OF KAPPA-CONOTOXIN PVIIA
GB0005124D0 (en) * 2000-03-03 2000-04-26 Cellpep Sa Maurocalcin,analogues thereof and their therapeutical uses
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011174707A (ja) * 2010-02-23 2011-09-08 Kanazawa Univ 心筋障害の検査方法

Also Published As

Publication number Publication date
CN1516596A (zh) 2004-07-28
CA2446839A1 (en) 2002-11-21
US20050049198A1 (en) 2005-03-03
AUPR506601A0 (en) 2001-06-07
NZ529940A (en) 2006-08-31
EP1392344A1 (en) 2004-03-03
BR0210902A (pt) 2004-06-08
EP1392344A4 (en) 2005-09-21
WO2002092119A1 (en) 2002-11-21
KR20040002970A (ko) 2004-01-07
ZA200309727B (en) 2005-08-01

Similar Documents

Publication Publication Date Title
Wisniewski et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro
JP2010503710A (ja) 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
JPH10327888A (ja) 新規ｇ−タンパク質結合レセプター（ｈｆｇａｎ７２ｘ）
JP2008517885A (ja) 化学修飾ペプチド類似体
CA2170727A1 (en) Methods and compositions for binding tau and map2c proteins
US7320959B2 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US20020077289A1 (en) Angiostatin and endostatin binding proteins and methods of use
WO2005007878A2 (en) Method of modulating apoptosis and compositions thereof
US20050049198A1 (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
JPH1175870A (ja) 新規なヒトｇ−タンパク質結合レセプター（ｈｃｅｐｔ０９）
JP2003523723A (ja) ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法
US7166584B1 (en) Cholesterol transport gene
US6930169B2 (en) Method of controlling the binding of calmyrin to presenilin
JP4800932B2 (ja) カルシウムイオンリーク抑制物
US7767417B2 (en) Prenyl-electrostatic switch, and methods of use
US7879563B2 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses
JP2002355051A (ja) 標 的
US7192702B2 (en) Modulators of the interaction between Arp2/3 and cortactin or HS-1
AU2002252850A1 (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
JP4694580B2 (ja) ヒトおよび哺乳動物の幹細胞由来神経生存因子
US20060252677A1 (en) Postsynaptic proteins
US20230227502A1 (en) Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them
WO2001062915A1 (fr) Nouvelle proteine et gene codant pour elle
Muretta Regulated traffic of Glut4
JPWO2000066145A1 (ja) 神経細胞株の細胞死を誘導する方法、神経細胞の細胞死を阻害または促進する化合物をスクリーニングする方法、ならびに神経細胞の細胞死の阻害剤および促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050517

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070621